NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Longfellow95,

Another rejection! Same story and i believe important for the dcvax-l appraisal.

NICE and cost-effectiveness estimate!

Europe’s first allogeneic stem cell therapy rejected by NICE.
20th August 2018

Cost regulators for the NHS in England and Wales have not approved funding for TiGenix and Takeda’s Alofisel - the first allogeneic stem cell therapy to be approved for use across the European Union – for use in Crohn’s patients.

Quote:

“However, in draft guidelines, the National Institute for Health and Care Excellence said Alofisel showed only a modest improvement in the proportion of people with complex perianal fistulas achieving complete remission compared with placebo in one clinical trial.

“Reliable follow-up results are only available for up to one year, so it is unclear how long the treatment benefit will last,” according to the guidelines.

Because of this, cost-effectiveness estimates are “highly uncertain” and the committee was unable to conclude on the most plausible cost-effectiveness estimate, NICE said.”

http://www.pharmatimes.com/news/europes_first_allogeneic_stem_cell_therapy_rejected_by_nice_1249435#.W3rPqkoedz4.linkedin?_lrsc=cea90543-f2de-4205-92eb-2a7b3025dd3e&utm_source=linkedin.com&utm_medium=referral&utm_term=&utm_content=Elevate&utm_campaign=LinkedIn-Elevate